Antioxidant properties of MDL and MMDL, two nicergoline metabolites, during chronic administration of haloperidol

Eur J Pharmacol. 2002 Oct 18;453(1):69-73. doi: 10.1016/s0014-2999(02)02386-5.

Abstract

We evaluated the effects of 10-alpha-methoxy-9,10-dihydrolysergol (MDL) and 1-methyl-10-alpha-methoxy-9,10-dihydrolysergol (MMDL), two nicergoline metabolites, during chronic treatment with haloperidol in rats. Haloperidol induced a significant decrease in the glutathione (GSH) content in selected areas of the brain and in the liver. Prolonged administration of MDL, MMDL or nicergoline antagonized the haloperidol-induced GSH decrease. Lipid peroxidation in the cortex and striatum was suppressed by MDL, MMDL or nicergoline administration. Our results show that MDL, MMDL and nicergoline have antioxidant activity, preventing not only GSH depletion but also lipid peroxidation. These observations suggest beneficial properties of MDL and MMDL in the treatment of neuroleptic-induced side effects.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Antioxidants / metabolism*
  • Antioxidants / pharmacology*
  • Brain / drug effects
  • Brain / metabolism
  • Glutathione / metabolism
  • Haloperidol / administration & dosage*
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Nicergoline / metabolism*
  • Nicergoline / pharmacology*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antioxidants
  • Adenosine Triphosphate
  • Glutathione
  • Haloperidol
  • Nicergoline